HOME >> MEDICINE >> NEWS
Zengen reports positive phase I/II trial results of its peptide molecule for vaginal yeast infection

(May 25, 2004) Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection. The open label, non-randomized study was designed to evaluate the safety, tolerability and pharmacokinetics of CZEN-002 in patients with VVC.

The majority of subjects in the study reported evidence of efficacy as determined by potassium hydroxide (KOH) tests and mycological cultures - 88.2 percent and 87.5 percent, respectively. A total of 20 female patients with VVC were enrolled and treated in the trial, and 17 completed the study. KOH testing and mycological cultures indicated that CZEN-002 is active and that five days of treatment provided positive evidence of anti-infective efficacy. CZEN-002 appeared safe and well-tolerated with no severe adverse reactions. In 100 percent of the plasma samples evaluated, concentrations of CZEN 002 were either not detected or were below the limit of quantitation.

"This trial clearly established the efficacy of CZEN-002," said William Smith, M.D., F.A.C.C., lead study investigator and associate professor, clinical medicine, at Tulane University School of Medicine and Louisiana State University Medical Center. "The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year with VVC."

The primary objective of the study was to evaluate the safety and tolerability of vaginally administered CZEN-002. A secondary objective was to assess the systemic absorption of CZEN-002 as determined by the plasma concentrations of the molecule through 21 days following dosing. The CZEN 002 was delivered to the 20 patients in a vaginal gel specifically designed for the purpose of the study.

"This clinical trial marks a major milestone for Zengen," said James M. Lipton, Ph.D., chief scientific officer of Zengen. "Our peptide appears to
'"/>

Contact: Cattaliya Snider
sniderc@ruderfinn.com
310-479-9929
Zengen
25-May-2004


Page: 1 2 3

Related medicine news :

1. Zengens new study reviews novel approach to control inflammation using melanocortin receptors
2. Lead in the environment causes violent crime, reports University of Pittsburgh researcher at AAAS
3. Study reports women dont experience undue pain, anxiety during mammography screening
4. Risks from labor after prior cesarean delivery low, study reports
5. Federal forum reports Americans aging well, but gaps remain
6. Early reports of thrombosis after insertion of drug-eluting stents
7. Study reports genetic susceptibility to alcoholism in NMDA receptor
8. Parents can provide accurate reports of their childrens ADHD symptoms
9. UCI Tobacco research center reports why teens are most vulnerable to smoking addiction
10. MIT reports new insights in visual recognition
11. Study reports improved method to identify fetal DNA in maternal blood samples

Post Your Comments:
(Date:4/1/2015)... (PRWEB) April 01, 2015 Pricing Healthcare ... last several months, bring coverage to a third of all ... states of Massachusetts, Kansas, and Iowa, and the first dedicated eye ... center in Dallas, TX was also added. , In addition, the ... to and general interest in the platform continue to grow across ...
(Date:4/1/2015)... With so much wet weather over the past ... their time indoors. When all this time is spent inside, ... latest article from Clean Crawls offers excellent advice to ... , One of the ways to improve the air ... The article states that, “Toluene, Xylene, and Benzene are all ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 "Giving credit ... to form. Its rewards are inestimable." - Loretta Young ... individuals in the water resources profession. The Call ... Please consider nominating yourself, a colleague, or organization for ... 2015. Learn more about the AWRA Awards and view ...
(Date:4/1/2015)... Decora Preset 30 Minute Countdown Timer, a ... Hardware City.’ The product helps in automatically switching off any ... the related electronic device is automatically turned off after the ... said, “We are glad that this amazing product is now ... Timer Switch in just a few clicks. The product has ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading provider ... and population health arenas, is pleased to announce a ... is fully integrated with the ACUITY platform. , The ... ET, will be led by Jeff Frater, RN, BSN, ... the feature-rich portal as well as the importance of ...
Breaking Medicine News(10 mins):Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 3Health News:Leviton Decora Preset 30 Minute Countdown Timer Available On TheHardwareCity.com 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3
(Date:4/1/2015)... 1, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, ... and cholesterol gallstones, today announced that it has ... of Clinical Operations. Mr. Tonelli brings ... development and regulatory affairs.  From 2005 to 2014, ...
(Date:4/1/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... company GmbH.  scil animal care is a highly specialized ... and services to veterinarians primarily in North ... on January 19, 2015. scil animal care ...
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
Cached News: